InvestorsHub Logo
Followers 7
Posts 304
Boards Moderated 0
Alias Born 10/30/2009

Re: None

Friday, 02/07/2014 1:04:23 PM

Friday, February 07, 2014 1:04:23 PM

Post# of 6805
I just got an an alert from Zacks Small Cap's research. This looks like a good entry point.

Senior Biotech analyst, Jason Napodano updated his report on DARA BioSciences, Inc. (DARA). In the report Jason details the specialty pharmaceutical company’s fourth quarter and full year financial results. Jason goes on to highlight insights from his meeting with management while attending the annual JP Morgan Healthcare Conference, as well as the parallel Biotech showcase and OneMedForum Conferences. Jason maintains his ‘Buy’ rating and $1.50 target price in this latest report.